SCHEMBL17835486

SCHEMBL17835486

O=C(Nc1nnc(-c2ccncc2)s1)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.68
RAB9A P51151 4/20 0.68
MEN1 O00255 2/20 0.68
KMT2A Q03164 2/20 0.68
RXFP1 Q9HBX9 2/20 0.68
CSNK2A2 P19784 2/20 0.63
CSNK2A1 P68400 2/20 0.63
KDM4E B2RXH2 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
APOBEC3G Q9HC16 2/20 0.59
APOBEC3A P31941 1/20 0.59
APOBEC3B Q9UH17 1/20 0.59
NOX1 Q9Y5S8 7/20 0.59
ALDH1A1 P00352 3/20 0.56
HSD17B10 Q99714 2/20 0.55
GAA P10253 1/20 0.55
HPGD P15428 1/20 0.55
RCE1 Q9Y256 1/20 0.55
DGAT1 O75907 1/20 0.55
LMNA P02545 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17318644 0.90 NPC1 (0.70) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL18292329 0.88 CSNK2A2 (0.74) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL17835800 0.88 NOX1 (0.70) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL17835805 0.86 NOX1 (0.71) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL17318624 0.85 RAB9A (0.79) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL17835774 0.83 NOX1 (0.67) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL17850804 0.83 NOX1 (0.67) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL17318598 0.81 NPC1 (0.65) NPC1RAB9AMEN1KMT2ARXFP1
SCHEMBL13357696 0.81 KDM4E (0.78) NPC1RAB9AMEN1KMT2ACSNK2A2
SCHEMBL18762150 0.81 BLM (0.70) NPC1RAB9AMEN1KMT2ARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190046515-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2019-02-14 US claimed
US-10130619-B2 Amido thiadiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2018-11-20 US claimed
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SUISSE SA (CH) 2017-12-07 US claimed
EP-3233847-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GenKyoTex Suisse SA (CH) 2017-10-25 EP claimed
WO-2016098005-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-06-23 WO claimed
EP-3034500-A1 Amido thiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2016-06-22 EP claimed
US-20190046515-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2019-02-14 US disclosed
US-20190046515-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2019-02-14 US disclosed
US-10130619-B2 Amido thiadiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2018-11-20 US disclosed
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SUISSE SA (CH) 2017-12-07 US disclosed
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SUISSE SA (CH) 2017-12-07 US disclosed
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SUISSE SA (CH) 2017-12-07 US disclosed
EP-3233847-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GenKyoTex Suisse SA (CH) 2017-10-25 EP disclosed
WO-2016098005-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-06-23 WO disclosed
WO-2016098005-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2016-06-23 WO disclosed
EP-3034500-A1 Amido thiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2016-06-22 EP disclosed
EP-3034500-A1 Amido thiazole derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2016-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348296-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX5, CYBB NPC1 2197/4885RAB9A 2324/4885MEN1 4380/4885
US-20190046515-A1 AMIDO THIADIAZOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX5, CYBB NPC1 2197/4885RAB9A 2324/4885MEN1 4380/4885
US-10130619-B2 Amido thiadiazole derivatives as NADPH oxidase inhibitors NOX1, NOX5, CYBB NPC1 2197/4885RAB9A 2324/4885MEN1 4380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.